Lantheus Holdings (LNTH) Share-based Compensation Growth (3y) (2017 - 2026)
Lantheus Holdings (LNTH) Share-based Compensation Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 10.06% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 9.14% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 0.43% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -8.13% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -1.73% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -8.04% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Lantheus Holdings | 6.52 Bn | 5.93 Bn | 241.86 Mn | 16.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.38% |
| Mar 31, 2026 | 17.53% |
| Dec 31, 2025 | -50.73% |
| Sep 30, 2025 | 44.60% |
| Jun 30, 2025 | 44.41% |
| Mar 31, 2025 | 62.66% |
| Dec 31, 2024 | -80.17% |
| Sep 30, 2024 | 73.98% |
| Jun 30, 2024 | 59.11% |
| Mar 31, 2024 | 129.85% |
| Dec 31, 2023 | -22.32% |
| Sep 30, 2023 | 51.84% |
| Jun 30, 2023 | -4.44% |
| Mar 31, 2023 | 46.49% |
| Dec 31, 2022 | 83.24% |
| Sep 30, 2022 | 33.27% |
| Jun 30, 2022 | 30.20% |
| Mar 31, 2022 | 70.01% |
| Dec 31, 2021 | 87.96% |
| Sep 30, 2021 | 17.12% |